Cancer Radiotherapie最新文献

{"title":"Extra- and intracranial schwannomas treated with fractionated stereotactic irradiation: Results of a retrospective, multicentric study","authors":"Caroline Beaudelot ,&nbsp;Virginie Delgrange ,&nbsp;Alexandre Coutte ,&nbsp;André-Michel Bimbai ,&nbsp;Marie-Cécile Le Deley ,&nbsp;Erwan Rault ,&nbsp;Xavier Mirabel ,&nbsp;Éric F. Lartigau ,&nbsp;David Pasquier ,&nbsp;Raphaëlle Mouttet-Audouard","doi":"10.1016/j.canrad.2025.104621","DOIUrl":"10.1016/j.canrad.2025.104621","url":null,"abstract":"<div><h3>Purpose</h3><div>Limited data exist on the role of fractionated stereotactic radiotherapy in the therapeutic strategy for neurinomas, particularly for extracranial locations. The objective of this study was to describe intra- and extracranial schwannomas using stereotactic body radiotherapy.</div></div><div><h3>Materials and methods</h3><div>A multicentric, non-interventional study was conducted using retrospectively collected data between January 2007 and September 2021. Patients who received fractionated stereotactic radiotherapy were included. Patient characteristics, data on localization, acute and chronic toxicity, local control, as well as progressive-free survival were collected.</div></div><div><h3>Results</h3><div>A total of 72 patients were included with 17 being treated with surgery beforehand. Intracranial localizations concerned nerve VIII (36 lesions), but also nerve IV, V, X and mixed nerves (XII). Extracranial localizations could be cervical, thoracic or lumbar. Treatment regimens were mainly delivering 36<!--> <!-->Gy in nine fractions of 4<!--> <!-->Gy (23.6 %) and 21<!--> <!-->Gy in three fractions of 7<!--> <!-->Gy (48.6 %). The median follow-up was 49.2 months. Local control was 84.8 % at 3 and 81.8 % at 5 years. Localization and dose schedule did not affect local control (<em>P</em> <!-->=<!--> <!-->0.67 and <em>P</em> <!-->=<!--> <!-->0.46 respectively). Besides surgery, no other factors were associated with local control (<em>P</em> <!-->=<!--> <!-->0.01). Two patients (5.0 %) experienced improvement in their hearing symptoms, while 35 (87.5 %) remained stable.</div></div><div><h3>Conclusion</h3><div>Our large multicentre study results add to evidence that fractionated stereotactic radiotherapy is a safe and effective treatment option for managing intracranial schwannomas but also extracranial localizations, including those of larger sizes.</div></div><div><h3>Objectif de l’étude</h3><div>Après la radiochirurgie des neurinomes, les études des 20 dernières années ont montré des taux de contrôle local favorables pour la radiothérapie stéréotaxique fractionnée. Il existe cependant peu de données sur le rôle de la radiothérapie stéréotaxique fractionnée dans la stratégie thérapeutique des neurinomes, en particulier pour les localisations extracrâniennes. L’objectif de cette étude était de décrire les résultats cliniques et le contrôle local.</div></div><div><h3>Matériel et méthodes</h3><div>Une étude multicentrique, non-interventionnelle, a été réalisée à partir de données collectées rétrospectivement au centre Oscar-Lambret à Lille et au centre hospitalier universitaire Amiens-Picardie en France entre janvier 2007 et septembre 2021. Les caractéristiques des patients, la localisation, la toxicité aiguë et chronique, le contrôle local, ainsi que la survie sans progression ont été recueillis.</div></div><div><h3>Résultats</h3><div>En tout, 72 patients ont été inclus, dont 17 avaient eu une chirurgie au préalable. Les lé","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 2","pages":"Article 104621"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143881699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term cardiac mortality in patients treated with radiation for gastric mucosa-associated lymphoid tissue lymphoma","authors":"Pierre Loap,&nbsp;Youlia Kirova","doi":"10.1016/j.canrad.2025.104588","DOIUrl":"10.1016/j.canrad.2025.104588","url":null,"abstract":"<div><h3>Purpose</h3><div>Limited-stage gastric mucosa-associated lymphoid tissue (MALT) lymphoma can be treated with radiation alone. Due to the immediate proximity of the stomach to the heart, there is a theoretical risk of radiation-induced cardiac toxicity, the incidence of which has never been precisely studied. The aim of this study was to assess cardiac-specific mortality in patients treated for gastric MALT lymphoma with radiation.</div></div><div><h3>Method</h3><div>This cohort study included all patients treated in the USA between 2000 and 2020 with radiation for gastric MALT lymphoma and whose clinical data were available in the Surveillance, Epidemiology and End Result database (17 registries). The primary endpoint was cardiac-specific survival. Assessed clinical variables were age, sex, race, stage of disease, type of treatment received and cause of death.</div></div><div><h3>Results</h3><div>A total of 1863 patients treated for MALT lymphoma with radiation were analysed. At 10<!--> <!-->years, cardiac-specific survival was 0.924 (95 % confidence interval [CI]: 0.906–0.942) and cancer-specific survival was 0.931 (95 %CI: 0.915–0.947), while non-cardiac/cancer-specific survival was 0.778 (95 %CI: 0.753–0.804). Cardiac-specific mortality was significantly higher in patients aged over 60<!--> <!-->years (hazard ratio [HR]: 9.07; <em>P</em> <!-->=<!--> <!-->0.002) and in cases of additional chemotherapy (HR: 1.83; <em>P</em> <!-->=<!--> <!-->0.017).</div></div><div><h3>Conclusion</h3><div>Cardiac mortality in patients treated with radiation for gastric MALT lymphoma represents a minor contribution compared with other causes of death. As new radiotherapy protocols should further minimize the risk of cardiac toxicity, and given the curability of this type of lymphoma, improving overall survival should also focus on the multidisciplinary management of comorbidities.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 1","pages":"Article 104588"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143512236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moderate versus ultra-hypofractionated locoregional breast radiotherapy: Results of a retrospective study during the covid-19 era","authors":"Paola Andrea Rivera ,&nbsp;Anne-Emmanuella Yéo ,&nbsp;Arnaud Dhénin ,&nbsp;Elisa Bodson ,&nbsp;Eléonore Brahy ,&nbsp;Julinne Stokart ,&nbsp;Lorraine Donnay ,&nbsp;Monique Seret ,&nbsp;Jean Vanderick ,&nbsp;Benoît Bihin ,&nbsp;Maxime Régnier ,&nbsp;Vincent Remouchamps","doi":"10.1016/j.canrad.2025.104593","DOIUrl":"10.1016/j.canrad.2025.104593","url":null,"abstract":"<div><h3>Purpose</h3><div>The use of ultra hypofractionated adjuvant breast radiotherapy for elderly patients was extended during the covid-19 pandemic. We compared its efficacy and safety versus moderate hypofractionation in elderly patients with breast cancer receiving locoregional radiotherapy at a single radiotherapy centre.</div></div><div><h3>Methods</h3><div>This retrospective analysis utilized routine patient data. Inclusion criteria comprised women aged 65 years or older with non-metastatic breast cancer, positive axillary nodes, and treated with locoregional radiotherapy following the ultra or moderate hypofractionation protocols. Outcomes studied included overall survival, disease-free survival, late normal tissue effects, and acute toxicity. Comparative analysis employed logistic regression and survival analysis with covariate adjustments.</div></div><div><h3>Results</h3><div>Two hundred and twenty-one patients were included, with a median age of 72.5 years (interquartile range [IQR]: 67.9–77.7 years) and a median follow-up of 36.3 months (IQR: 25.4–47.8 months). No significant differences were found in overall and disease-free survival rates between ultra and moderate hypofractionation protocols (adjusted hazard ratio [HR] for death: 0.81, 95 % confidence interval [CI]: 0.27–2.46, <em>P</em> <!-->=<!--> <!-->0.712; adjusted HR for relapse or death: 0.96, 95 % CI: 0.39–2.37, <em>P</em> <!-->=<!--> <!-->0.923). Although ultra-hypofractionation showed an increase in moderate late-onset breast oedema, no significant differences were observed regarding other more common moderate adverse events, such as acute dermatitis and late-onset homolateral arm oedema.</div></div><div><h3>Conclusion</h3><div>Our retrospective analysis suggests that the ultra-hypofractionation protocol for locoregional irradiation in elderly patients with breast cancer maintains an acceptable safety profile and shows no significant difference in efficacy compared to the moderate hypofractionation schedule. Prospective confirmation is awaited.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 1","pages":"Article 104593"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143593130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between radiotherapy and risk of secondary primary malignancies in patients with esophageal cancer: A population-based study utilizing 17 Surveillance, Epidemiology, and End Results cancer registries","authors":"Wenjie Li,&nbsp;Wei Wang","doi":"10.1016/j.canrad.2024.07.020","DOIUrl":"10.1016/j.canrad.2024.07.020","url":null,"abstract":"<div><h3>Purpose</h3><div>Despite the frequent use of radiotherapy as a standard treatment for esophageal cancer, the potential risk of developing second primary malignancies as a result of radiation-related side effects remains underinvestigated.</div></div><div><h3>Methods</h3><div>We conducted a comprehensive analysis using data from the large cohort of 17 cancer registries within the Surveillance, Epidemiology, and End Results (SEER) database. To estimate the incidence of second primary malignancies associated with radiotherapy, we employed Poisson regression and competing risk regression models.</div></div><div><h3>Results</h3><div>A total of 54,844 patients diagnosed with esophageal cancer were identified from the SEER database. Among them, 8351 patients did not receive radiotherapy, while 15,555 patients were treated with radiation. The incidence of second primary malignancies among patients who had radiotherapy was 6.28 % (977 patients) compared to an incidence of 7.09 % (592 patients) for those who had not (<em>P</em> <!-->&lt;<!--> <!-->0.0001). After adjusting for potential confounders, such as age, gender, year of diagnosis, tumor grade, and chemotherapy, the incidence rates of patients who received radiotherapy were significantly higher compared to those who had not (odds ratio [OR] _Poisson _regression <!-->=<!--> <!-->1.18, 95 % confidence interval [CI]: 1.05–1.32, <em>P</em> <!-->=<!--> <!-->0.018; OR _{multivariable} _competing _risk _regression <!-->=<!--> <!-->1.15, 95 %CI: 1.04–1.26, <em>P</em> <!-->=<!--> <!-->0.018). Notably, patients who received radiotherapy were found to be at an increased risk of developing lung cancer, breast cancer, and gastric cancer. Additionally, younger patients with esophageal cancer appeared to be more susceptible, with the highest risk of developing subsequent primary malignancies observed more than 10 years after the esophageal cancer diagnosis.</div></div><div><h3>Conclusion</h3><div>Our findings indicated that radiotherapy for esophageal cancer was associated with an increased risk of developing overall cancer. It is crucial to address and mitigate the risk of second primary malignancies associated with radiotherapy, while also improving the prognosis for patients affected by these secondary malignancies.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 1","pages":"Article 104587"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypertension and hypotension due to baroreceptors dysfunction: A physician personal experience as a head and neck cancer patient","authors":"Itzhak Brook","doi":"10.1016/j.canrad.2024.05.009","DOIUrl":"10.1016/j.canrad.2024.05.009","url":null,"abstract":"<div><div>Radiation to the head and neck can damage the baroreceptors located in the carotid artery. These baroreceptors help in regulating blood pressure by detecting the pressure of blood flowing through them, and sending messages to the central nervous system to increase or decrease the peripheral vascular resistance and cardiac output. Some individual treated with radiation develop low, labile or paroxysmal hypertension. This manuscript describes my personal experiences as well as other head and neck cancer survivors who received radiation therapy and experienced baroreceptor dysfunction. These personal testimonials highlight the need to educate clinicians about the diagnosis and treatment of vestibular dysfunction including paroxysmal hypertension.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 1","pages":"Article 104585"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring treatment complexity in maxillary ameloblastoma: A case study on the efficacy of radiotherapy with transcriptomic and literature insights","authors":"Léa Marxgut ,&nbsp;Philippe Fourneret ,&nbsp;Waisse Waissi","doi":"10.1016/j.canrad.2025.104591","DOIUrl":"10.1016/j.canrad.2025.104591","url":null,"abstract":"<div><div>In this report, we describe the case of a patient initially experiencing symptoms including nasal obstruction and rhinorrhoea, leading to surgeries and a diagnosis of ameloblastoma. Despite complete surgical resections, MRI follow-ups indicated tumour regrowth, prompting a shift to radiotherapy. The treatment plan involved a high-dose (60<!--> <!-->Gy in 30 fractions of 2<!--> <!-->Gy) volumetric modulated arc therapy. During treatment, the patient experienced minimal side effects and showed significant clinical improvement, including tumour size reduction and resolution of facial paralysis. Follow-up MRI confirmed shrinkage of the tumour, with some persistent symptoms like diplopia. To better understand the radiosensitivity of ameloblastomas, transcriptomic analysis highlighted the potential of a radiosensitivity index to predict treatment response, indicating ameloblastomas exhibit higher radiosensitivity compared to odontogenic keratocysts. Finally, literature analysis showed a small number of cases with wide range of radiation dose. In conclusion, the case illustrates the complex diagnostic journey of ameloblastomas and underscores the efficacy of radiotherapy for inoperable cases, and the importance of predictive biomarkers to enhance treatment outcomes.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 1","pages":"Article 104591"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143534258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Radiothérapie reviewers in 2024","authors":"","doi":"10.1016/j.canrad.2025.104602","DOIUrl":"10.1016/j.canrad.2025.104602","url":null,"abstract":"","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 1","pages":"Article 104602"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cyberneo trial investigating the efficacy of stereotactic radiotherapy combined to neoadjuvant chemotherapy for locally advanced breast cancer: 14-years follow-up results","authors":"Syrine Ben Dhia ,&nbsp;Renaud Schiappa ,&nbsp;Jocelyn Gal ,&nbsp;Jean-Marc Ferrero ,&nbsp;Philippe Bahadoran ,&nbsp;Claire Chapellier ,&nbsp;Pierre-Yves Bondiau","doi":"10.1016/j.canrad.2025.104592","DOIUrl":"10.1016/j.canrad.2025.104592","url":null,"abstract":"<div><h3>Purpose</h3><div>The purpose of the phase I trial named “Cyberneo” was to define the efficacy of the stereotactic radiotherapy using CyberKnife® for locally advanced (stage III) breast tumours combined to a neoadjuvant chemotherapy for patients for whom a conservative surgery could not be considered at the onset. Neoadjuvant chemotherapy consisted of six cycles: three cycles of docetaxel and three cycles of the combination of 5-fluorouracil, epirubicin and cyclophosphamide. Stereotactic radiotherapy using CyberKnife® was performed during the second cycle of chemotherapy. Breast surgery was performed 6 to 8 weeks later and conventional breast irradiation without boost, afterwards. The main objective was to define the maximum tolerated dose of hypofractionated radiotherapy concurrent with neoadjuvant chemotherapy. We present an updated survival data for patients included in this trial and we evaluate the late toxicity of this combination.</div></div><div><h3>Patients and methods</h3><div>We updated the survival data of 25 patients treated for a stage III breast cancer between 2007 and 2009 at the Antoine-Lacassagne centre in Nice and included in the Cyberneo trial by recording late toxicity events and aesthetic results.</div></div><div><h3>Results</h3><div>With a median follow-up of 12 years (95 % confidence interval [CI]: 10–14 years), 19 patients were in remission (76 %), one patient had a controlled axillary lymph node relapse (4 %) and five patients (20 %) died due to metastatic progression within a median of 5 years after treatment (range: 1–9 years). Nine patients had a complete histological response (36 %). The highest percentage of complete histological response was in the group of patients treated in the fourth stage (28.5<!--> <!-->Gy in four fractions). Overall survival rate at 14 years was 71 % (95 % CI: [53–94 %]). Two patients developed chronic radiation toxicity during follow-up with a fibrosis (8 %) of which one was in the fourth stage and one in the fifth stage (31.5<!--> <!-->Gy). Three patients (12 %) had a change of prosthesis after treatment, which for one patient was 24 months after the end of support.</div></div><div><h3>Conclusion</h3><div>The updated results of the Cyberneo trial with 14 years of follow-up confirm the satisfactory results in terms of local control with an excellent long-term safety profile.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 1","pages":"Article 104592"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143512238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does prior radiotherapy impact the acute cellular liver graft rejection?","authors":"Julien Pierrard ,&nbsp;Maxime Foguenne ,&nbsp;Pamela Baldin ,&nbsp;Eliano Bonaccorsi-Riani ,&nbsp;Laurent Coubeau ,&nbsp;Olga Ciccarelli ,&nbsp;Géraldine Dahlqvist ,&nbsp;Bénédicte Delire ,&nbsp;Geneviève Van Ooteghem","doi":"10.1016/j.canrad.2025.104590","DOIUrl":"10.1016/j.canrad.2025.104590","url":null,"abstract":"<div><h3>Purpose</h3><div>Radiotherapy can be used as a bridge therapy prior to liver transplantation. Radiotherapy generates immune reactions involving T cells, which are the main effectors of acute cellular rejection after transplantation. Here, we investigated the impact of radiotherapy on acute cellular rejection.</div></div><div><h3>Materials and methods</h3><div>We retrospectively reviewed the data of oncological patients who benefited from liver transplantation. Patients who received radiotherapy prior to liver transplantation (“RT cohort”, <em>n</em> <!-->=<!--> <!-->17) were compared to a matched cohort (“NoRT_matched cohort”, <em>n</em> <!-->=<!--> <!-->17) obtained through propensity score-matching analysis of the total non-irradiated cohort (“NoRT_all” cohort, <em>n</em> <!-->=<!--> <!-->136). The acute cellular rejection was evaluated using the Banff score for rejection (mild:<!--> <!-->&lt;<!--> <!-->5, moderate: 5–6, and severe: 7–9) obtained on an early post-transplantation biopsy. Overall and disease-free survival were reported for patients with hepatocellular carcinoma.</div></div><div><h3>Results</h3><div>Median Banff scores was significantly lower for the RT cohort compared to the NoRT_all cohort (2.5 versus 5, respectively, <em>P</em> <!-->=<!--> <!-->0.043) but this statistical difference was eliminated after comparison with the NoRT_matched cohort (median: 4, <em>P</em> <!-->=<!--> <!-->0.62). The 5-year overall and disease-free survival rates were 62 % and 69 %, respectively, for hepatocellular carcinoma patients of the RT cohort (<em>n</em> <!-->=<!--> <!-->14) and did not differ from the 5-year overall (83 %, <em>P</em> <!-->=<!--> <!-->0.15) and disease-free survival rates (90 %, <em>P</em> <!-->=<!--> <!-->0.05) of those of the NoRT_matched cohort (<em>n</em> <!-->=<!--> <!-->16).</div></div><div><h3>Conclusion</h3><div>Radiotherapy given prior to liver transplantation did not impact the rate or severity of acute cellular rejection. Furthermore, overall and disease-free survival rates were not impacted by radiotherapy.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 1","pages":"Article 104590"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cone-beam CT radiomics for early response assessment in liver stereotactic body radiation therapy: Results of a pilot study","authors":"Jingjing Shan ,&nbsp;Pengfei Yang ,&nbsp;Eric Yen ,&nbsp;Qinxuan Zhou ,&nbsp;Benxing Gu ,&nbsp;Xuyun Xie ,&nbsp;Jing Wang ,&nbsp;Tianye Niu ,&nbsp;Xiaonan Sun","doi":"10.1016/j.canrad.2024.05.010","DOIUrl":"10.1016/j.canrad.2024.05.010","url":null,"abstract":"<div><h3>Purpose</h3><div>The objective of the study was to assess the correlation between radiomics features extracted from cone-beam CT with the treatment response of liver tumors treated with stereotactic body radiation.</div></div><div><h3>Material and methods</h3><div>The planning CT and cone-beam CT were prospectively collected for 76 patients with liver cancer who received five fractions of stereotactic body radiation therapy. Pearson correlation test was used to identify interchangeable radiomics features between cone-beam- and planning CT from a total of 547 extracted radiomics features. Principal components analysis was used for cone-beam CT delta radiomics to characterize therapy-induced tumor change. The Mann-Whitney U-test was used to identify features with correlation to treatment response: local efficacy versus local non-efficacy; complete versus partial response in both raw and principal components analysis-based cone-beam CT radiomics features. The area under the receiver operating characteristic curve was used for assessing feature performance.</div></div><div><h3>Results</h3><div>A total of 345 cone-beam CT radiomics features were interchangeable with planning CT. The mean value of LHH_GLSZM_LGZE showed an ascending trend in five fractions during the course of treatment. Among these features, PCA3_LHH_Histogram_Energy showed the best performance in predicting local efficacy, with an AUC of 0.879 (0.744–1.00, 95 % CI). For identifying complete response from partial response, CBCT2_LHL_GLSZM_GLV showed the best value, with the highest AUC of 0.884 (0.773–1.00, 95 % CI).</div></div><div><h3>Conclusion</h3><div>Radiomics features extracted from cone-beam CT images have the potential for assessing the response to treatment in advance and can serve as an early biomarker for liver tumor stereotactic body radiation therapy.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 1","pages":"Article 104586"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}